JHOP - June 2020 Vol 10, No 3

June 2020 Vol 10, No 3

Kelsey Konrardy, PharmD, Kane M. Hosmer, PharmD, BCOP, Michelle Rockey, PharmD, BCOP, FHOPA, Zahra Mahmoudjafari, PharmD, BCOP, Dennis W. Grauer, MS, PhD, David W. Henry, MS, RPh, BCOP, FASHP, Leyla Shune, MD, Joseph McGuirk, DO

JHOP - June 2020 Vol 10, No 3 - Original Research

Monitoring Methotrexate Levels in a Patient After Glucarpidase Administration: A Case Report

Savannah L. Gulley, PharmD, Kyle A. Franco, PharmD, BCPPS, Joshua J. Elder, PharmD, BCPS, BCOP

JHOP - June 2020 Vol 10, No 3 - Case Reports

High-dose methotrexate is an integral component of treatment regimens for a variety of pediatric malignancies, including osteosarcoma, acute lymphoblastic leukemia, and non-Hodgkin lymphoma.

What’s New in the Oncology Drug Pipeline?

Meg Barbor, MPH

JHOP - June 2020 Vol 10, No 3 - HOPA Abstracts

The Intersection of Immunotherapy and Targeted Therapy in Lung Cancer

Meg Barbor, MPH

JHOP - June 2020 Vol 10, No 3 - HOPA Abstracts

The Cancer Care Gap in Rural America: A 50-Million People Conundrum

Meg Barbor, MPH

JHOP - June 2020 Vol 10, No 3 - HOPA Abstracts

Direct Oral Anticoagulant Therapy for Heparin-Induced Thrombocytopenia—A New Alternative?

Zain Al-Jammali, PharmD, Harleen Singh, PharmD, BCACP, Dr. Joseph Bubalo, PharmD, BCPS, BCOP, Joseph Shatzel, MD

JHOP - June 2020 Vol 10, No 3 - Symptom Management

Heparin-induced thrombocytopenia (HIT) is an immune-mediated thrombocytopenia and prothrombotic disorder that occurs in a minority of patients exposed to unfractionated or low-molecular-weight heparin (LMWH).

HOPA 2020 Abstracts

JHOP - June 2020 Vol 10, No 3 - HOPA Abstracts

This is the first selection of abstracts presented at the 16th Annual Conference of HOPA in Tampa, FL, in April 2020. Additional posters are being published in subsequent issues of the journal.

Results 1 - 9 of 9